Emerging Business Models in Biopharma - Drug Discovery TOE

USD 950.00

* Required Fields

USD 950.00


Be the first to review this product

This edition of the Drug Discovery TOE depicts the current landscape and the new life sciences trends across emerging business models in the biopharmaceutical industry. The corresponding patent scenario is depicted, along with the industry interactions..The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnolog

Table of Contents

Emerging Business Models in Biopharma - Drug Discovery TOETrend OverviewEmerging Business Models in BiopharmaEmerging Business Models in BiopharmaTechnology ProfilesProof of Concept ModelValue Enabling Model Lean Innovation ModelOutcome Focused Model Collaborative Business ModelOutcome Focused ModelCollaborative Business ModelStrategic InsightsTrends Transforming the Healthcare Value ChainStrategies Driving Biopharma EvolutionAppendixPatent AnalysisPatent AnalysisIndustry InteractionsIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.